피부 화상 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Skin Burn Market Outlook

Thelansis's "Skin Burn Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Skin Burn treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Skin Burn Overview

A skin burn is an injury caused by heat, chemicals, electricity, or radiation that can range from superficial damage to full-thickness wounds incapable of healing without intervention. Extensive burns have traditionally been treated with autologous skin grafting, but this approach is limited by the availability of healthy donor skin. This has driven the development of engineered skin substitutes and cell-based therapies that expand a patient's own skin cells or provide temporary biological coverage to promote healing and reduce scarring. More advanced regenerative approaches, including 3D bioprinting, are being investigated to restore functional skin rather than simply replace lost tissue. In some healthcare systems, recent changes in reimbursement for advanced skin substitutes are also influencing where and how these therapies are delivered. For stakeholders, burn care illustrates how clinical innovation and reimbursement policy together shape patient access to advanced treatments.

Key Highlights

• In Germany, incident Skin Burn cases are projected to increase from 319,485 in 2025 to 325,306 by 2035.
• Skin burns remain a major cause of hospitalization, long-term disability, and healthcare burden.
• Severe burns require specialized wound care to reduce complications and improve recovery.
• Significant unmet need remains for advanced therapies that accelerate wound healing and minimize scarring.

Market Overview

• The France Skin Burns market is projected to grow from $50M in 2025 to $85M by 2035.
• Market growth is driven by:
• Increasing adoption of advanced wound care and skin regeneration therapies
• Ongoing innovation in biologics and tissue-engineered products
• Future growth will depend on therapies that improve healing outcomes and reduce long-term complications.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)